Intercept Pharma Says it Expects To Read-Out Top-Line Data From the Interim Analysis of its Phase 3 REGENERATE Trial in Q1 2019, Plans to Complete Enrollment of its Phase 3 REVERSE Trial in 2019
Benzinga Newsdesk